HCV - Serono's 2005 Adjusted(i) EPS Increased by 34.6%

Serono's 2005 Adjusted(i) EPS Increased by 34.6%
PR Newswire (press release), NY - Feb 5, 2006... two phase III programs - r-hGH in HIV-associated adipose redistribution syndrome (HARS) - IFN-beta 1a with or without ribavirin in chronic hepatitis C in Asian ...

Peregrine Antiviral Demonstrates Safety in Hepatitis Patients
International News Service, Australia - Feb 28, 2006... data demonstrating that its first-in-class antiviral compound Tarvacin appeared safe and well-tolerated in a phase I study in patients with chronic hepatitis C ...

Human Genome Sciences Reports Financial Results for Full Year and ...
MSN Money - Feb 9, 2006... November 2005, HGS reported the interim results of a Phase 2 trial of Albuferon in combination with ribavirin in patients with chronic hepatitis C who failed ...

XTL Biopharmaceuticals to Present at the JPMorgan Small Cap ...
PR Newswire (press release), NY - Feb 13, 2006... of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C ...